Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Several companies rightfully used the heavily sought-after screen time to raise awareness and send powerful messages, and it ...

Direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention side effects of the drugs.

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

After a telehealth company's Super Bowl commercial sparked nationwide debate about pharmaceutical safety and advertising, one DSO executive is reflecting on what the controversy means for patient care ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the FDA.